Kelyniam Global Posts 35% Revenue Growth and Return to Profitability in First Nine Months of 2026
Gross profit grew faster than revenue, rising 41% versus revenue growth of 35% over the nine-month period.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kelyniam Global (KLYG) reported 35% revenue growth for the nine months ended September 30, 2026, alongside a return to operating profitability. Revenue reached $2,954,087, compared with $2,186,491 in the same period of 2025. Gross profit increased 41% to $2,383,632 from $1,695,496. Operating income was $244,509, compared with an operating loss of $162,373 a year earlier.
CustomizedBone unit sales more than doubled year over year. The company attributed its financial results to the Fusion launch and higher CustomizedBone unit sales. Complete unaudited financial results for Q3 2026, including detailed breakdowns and cash flow statements, will be available on Kelyniam's website; the figures disclosed here cover the nine-month period.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointRevenue increased 35% to $2,954,087 for the nine months ended September 30, 2026, versus $2,186,491 a year earlier.
- Moderate pointOperating income reached $244,509 for the nine-month period, versus a prior-year operating loss of $162,373.
- Minor pointGross profit rose 41% to $2,383,632 for the nine-month period, versus $1,695,496 a year earlier.
- Minor pointCustomizedBone unit sales more than doubled year over year.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, CT / ACCESS Newswire / November 10, 2026 / Kelyniam Global, Inc. (OTCID:KLYG), a leader in custom cranial and craniofacial implants, today reported financial results for the nine months ended September 30, 2026.
Financial Highlights (Nine months ended September 30, 2026 vs. September 30, 2025)
- Revenue of
$2,954,087 , compared to$2,186,491 , an increase of35% . - Gross profit of
$2,383,632 , compared to$1,695,496 , an increase of41% . - Operating income of
$244,509 , compared to an operating loss of$(162,373) in the prior-year period.
Fusion™ BCP-PEEK implants combine the strength and radiolucency of PEEK with biphasic calcium phosphate to promote osteointegration, and can be designed, manufactured, and delivered overnight. CustomizedBone™ unit sales more than doubled year over year. Indicated for pediatric patients as young as seven, it fully integrates into the skull and is associated with a lower infection rate than many alternatives.
"Our strong financial results reflect the successful launch of Fusion™ and higher unit sales of CustomizedBone™," said Kris Renton, Chief Operating Officer of Kelyniam Global. "Surgeons are recognizing the clinical value of these advanced biomaterials, which support our commitment to leadership in regenerative custom cranial implants. Fusion's expedited delivery, integrated fixation tabs, and osteointegration benefits, combined with CustomizedBone's ability to incorporate the patient's own bone and lower infection risk, give surgeons distinct options for cranial reconstruction."
Kelyniam's complete unaudited financial results for Q3 2026, including detailed breakdowns and cash flow statements, will be available on the company's website at https://kelyniam.com/media.
About Kelyniam Global, Inc.
Kelyniam Global, Inc. (OTCID:KLYG) designs, manufactures, and distributes custom cranial and craniofacial implants using advanced biocompatible materials. Renowned for its industry-leading 24-48 hour delivery, Kelyniam partners with surgeons, hospitals, and payors to optimize clinical outcomes and reduce costs in neurosurgery. For more information, visit www.kelyniam.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Such risks include market competition, regulatory delays, distributor performance variability, economic pressures on healthcare spending, and supply chain disruptions, as detailed in Kelyniam's filings with the Securities and Exchange Commission. Kelyniam undertakes no obligation to update these statements except as required by law.
Investor Contact: Ross Bjella, Rbjella@kelyniam.com
(860) 590-3034 | info@kelyniam.com
Phone: (800) 280-8192
Email: Info@kelyniam.com
Address: 97 River Road, Canton, CT 06019
SOURCE: Kelyniam Global, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Did Kelyniam Global return to profitability in the first nine months of 2026?
Kelyniam reported operating income of $244,509 for the nine months ended September 30, 2026, compared with an operating loss of $162,373 in the prior-year period. The disclosed profitability measure is operating income.